Loading…
Alkylglycerols reduce serum complement and plasma vascular endothelial growth factor in obese individuals
Alkylglycerols (AKGs), isolated or present in shark liver oil have anti-inflammatory properties. Complement 3 (C3) and 4 (C4) participate in lipid metabolism and in obesity, contributing to the metabolic syndrome and to the low-grade inflammation associated with obesity. In a randomized, controlled,...
Saved in:
| Published in: | Inflammopharmacology 2016-06, Vol.24 (2-3), p.127-131 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-p217t-1d2dc724670a9b2cbb87fb2bbcd3d22eb7d0de467cf3cb80e66a5652a42ad62e3 |
| container_end_page | 131 |
| container_issue | 2-3 |
| container_start_page | 127 |
| container_title | Inflammopharmacology |
| container_volume | 24 |
| creator | Parri, A. Fitó, Montserrat Torres, C. F. Muñoz-Aguayo, D. Schröder, H. Cano, J. F. Vázquez, L. Reglero, G. Covas, María-Isabel |
| description | Alkylglycerols (AKGs), isolated or present in shark liver oil have anti-inflammatory properties. Complement 3 (C3) and 4 (C4) participate in lipid metabolism and in obesity, contributing to the metabolic syndrome and to the low-grade inflammation associated with obesity. In a randomized, controlled, crossover study, 26 non-diabetes obese individuals were assigned two preparations with low (LAC, 10 mg AKGs) and high (HAC, 20 mg AKGs) AKG content. Intervention periods were of 3 weeks preceded by 2-week washout periods in which shark liver oil was avoided. Cholesterol, C3, C4, and vascular endothelial growth factor (VEGF) decreased in a linear trend (
P
|
| doi_str_mv | 10.1007/s10787-016-0265-4 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1888966739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1888966739</sourcerecordid><originalsourceid>FETCH-LOGICAL-p217t-1d2dc724670a9b2cbb87fb2bbcd3d22eb7d0de467cf3cb80e66a5652a42ad62e3</originalsourceid><addsrcrecordid>eNqFkU9P4zAQxS20CLrAB-CCfNxLFnvS2M6xqtgFCYnL7tnyn2kJOHGwk6J-e1y1e97TG837aaQ3j5Bbzn5yxuR95kwqWTEuKgaiqZZnZMEboapGMPWNLFgLZSlauCTfc35jjAkp2gtyCZIr1Sq5IN0qvO_DNuwdphgyTehnhzRjmnvqYj8G7HGYqBk8HYPJvaE7k90cTKI4-Di9YuhMoNsUP6dXujFuiol2A40WM5bBd7vOzybka3K-KYI3J70if389_Fk_Vs8vv5_Wq-dqBC6ninvwTsJSSGZaC85aJTcWrHW-9gBopWcei-02tbOKoRCmEQ2YJRgvAOsr8uN4d0zxY8Y86b7LDkMwA8Y565JctULIuv0_KluoZQ38gN6d0Nn26PWYut6kvf73yQLAEcjFGraY9Fuc01CSas70oS59rEuXuvShLr2svwBWlohD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1792373219</pqid></control><display><type>article</type><title>Alkylglycerols reduce serum complement and plasma vascular endothelial growth factor in obese individuals</title><source>Springer Nature</source><creator>Parri, A. ; Fitó, Montserrat ; Torres, C. F. ; Muñoz-Aguayo, D. ; Schröder, H. ; Cano, J. F. ; Vázquez, L. ; Reglero, G. ; Covas, María-Isabel</creator><creatorcontrib>Parri, A. ; Fitó, Montserrat ; Torres, C. F. ; Muñoz-Aguayo, D. ; Schröder, H. ; Cano, J. F. ; Vázquez, L. ; Reglero, G. ; Covas, María-Isabel</creatorcontrib><description>Alkylglycerols (AKGs), isolated or present in shark liver oil have anti-inflammatory properties. Complement 3 (C3) and 4 (C4) participate in lipid metabolism and in obesity, contributing to the metabolic syndrome and to the low-grade inflammation associated with obesity. In a randomized, controlled, crossover study, 26 non-diabetes obese individuals were assigned two preparations with low (LAC, 10 mg AKGs) and high (HAC, 20 mg AKGs) AKG content. Intervention periods were of 3 weeks preceded by 2-week washout periods in which shark liver oil was avoided. Cholesterol, C3, C4, and vascular endothelial growth factor (VEGF) decreased in a linear trend (
P
< 0.01) from baseline (control) to LAC and HAC. Values after HAC were significantly lower (
P
< 0.05) versus both baseline and after LAC. No adverse effects were observed or reported. Data from this pilot study open a promising field for the study of the beneficial effects of AKGs on cardiovascular risk factors in obese individuals.</description><identifier>ISSN: 0925-4692</identifier><identifier>EISSN: 1568-5608</identifier><identifier>DOI: 10.1007/s10787-016-0265-4</identifier><identifier>PMID: 27188987</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject><![CDATA[Adult ; Allergology ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - isolation & purification ; Biomarkers - blood ; Biomedical and Life Sciences ; Biomedicine ; Cross-Over Studies ; Dermatology ; Double-Blind Method ; Female ; Fish Oils - administration & dosage ; Fish Oils - isolation & purification ; Gastroenterology ; Glycerol - administration & dosage ; Glycerol - isolation & purification ; Humans ; Immunology ; Male ; Middle Aged ; Obesity - blood ; Obesity - diagnosis ; Obesity - diet therapy ; Pharmacology/Toxicology ; Pilot Projects ; Rheumatology ; Short Communication ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vascular Endothelial Growth Factor A - blood ; Young Adult]]></subject><ispartof>Inflammopharmacology, 2016-06, Vol.24 (2-3), p.127-131</ispartof><rights>Springer International Publishing 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-p217t-1d2dc724670a9b2cbb87fb2bbcd3d22eb7d0de467cf3cb80e66a5652a42ad62e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27188987$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parri, A.</creatorcontrib><creatorcontrib>Fitó, Montserrat</creatorcontrib><creatorcontrib>Torres, C. F.</creatorcontrib><creatorcontrib>Muñoz-Aguayo, D.</creatorcontrib><creatorcontrib>Schröder, H.</creatorcontrib><creatorcontrib>Cano, J. F.</creatorcontrib><creatorcontrib>Vázquez, L.</creatorcontrib><creatorcontrib>Reglero, G.</creatorcontrib><creatorcontrib>Covas, María-Isabel</creatorcontrib><title>Alkylglycerols reduce serum complement and plasma vascular endothelial growth factor in obese individuals</title><title>Inflammopharmacology</title><addtitle>Inflammopharmacol</addtitle><addtitle>Inflammopharmacology</addtitle><description>Alkylglycerols (AKGs), isolated or present in shark liver oil have anti-inflammatory properties. Complement 3 (C3) and 4 (C4) participate in lipid metabolism and in obesity, contributing to the metabolic syndrome and to the low-grade inflammation associated with obesity. In a randomized, controlled, crossover study, 26 non-diabetes obese individuals were assigned two preparations with low (LAC, 10 mg AKGs) and high (HAC, 20 mg AKGs) AKG content. Intervention periods were of 3 weeks preceded by 2-week washout periods in which shark liver oil was avoided. Cholesterol, C3, C4, and vascular endothelial growth factor (VEGF) decreased in a linear trend (
P
< 0.01) from baseline (control) to LAC and HAC. Values after HAC were significantly lower (
P
< 0.05) versus both baseline and after LAC. No adverse effects were observed or reported. Data from this pilot study open a promising field for the study of the beneficial effects of AKGs on cardiovascular risk factors in obese individuals.</description><subject>Adult</subject><subject>Allergology</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - isolation & purification</subject><subject>Biomarkers - blood</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cross-Over Studies</subject><subject>Dermatology</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Fish Oils - administration & dosage</subject><subject>Fish Oils - isolation & purification</subject><subject>Gastroenterology</subject><subject>Glycerol - administration & dosage</subject><subject>Glycerol - isolation & purification</subject><subject>Humans</subject><subject>Immunology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Obesity - blood</subject><subject>Obesity - diagnosis</subject><subject>Obesity - diet therapy</subject><subject>Pharmacology/Toxicology</subject><subject>Pilot Projects</subject><subject>Rheumatology</subject><subject>Short Communication</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Vascular Endothelial Growth Factor A - blood</subject><subject>Young Adult</subject><issn>0925-4692</issn><issn>1568-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFkU9P4zAQxS20CLrAB-CCfNxLFnvS2M6xqtgFCYnL7tnyn2kJOHGwk6J-e1y1e97TG837aaQ3j5Bbzn5yxuR95kwqWTEuKgaiqZZnZMEboapGMPWNLFgLZSlauCTfc35jjAkp2gtyCZIr1Sq5IN0qvO_DNuwdphgyTehnhzRjmnvqYj8G7HGYqBk8HYPJvaE7k90cTKI4-Di9YuhMoNsUP6dXujFuiol2A40WM5bBd7vOzybka3K-KYI3J70if389_Fk_Vs8vv5_Wq-dqBC6ninvwTsJSSGZaC85aJTcWrHW-9gBopWcei-02tbOKoRCmEQ2YJRgvAOsr8uN4d0zxY8Y86b7LDkMwA8Y565JctULIuv0_KluoZQ38gN6d0Nn26PWYut6kvf73yQLAEcjFGraY9Fuc01CSas70oS59rEuXuvShLr2svwBWlohD</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Parri, A.</creator><creator>Fitó, Montserrat</creator><creator>Torres, C. F.</creator><creator>Muñoz-Aguayo, D.</creator><creator>Schröder, H.</creator><creator>Cano, J. F.</creator><creator>Vázquez, L.</creator><creator>Reglero, G.</creator><creator>Covas, María-Isabel</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20160601</creationdate><title>Alkylglycerols reduce serum complement and plasma vascular endothelial growth factor in obese individuals</title><author>Parri, A. ; Fitó, Montserrat ; Torres, C. F. ; Muñoz-Aguayo, D. ; Schröder, H. ; Cano, J. F. ; Vázquez, L. ; Reglero, G. ; Covas, María-Isabel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p217t-1d2dc724670a9b2cbb87fb2bbcd3d22eb7d0de467cf3cb80e66a5652a42ad62e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Allergology</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - isolation & purification</topic><topic>Biomarkers - blood</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cross-Over Studies</topic><topic>Dermatology</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Fish Oils - administration & dosage</topic><topic>Fish Oils - isolation & purification</topic><topic>Gastroenterology</topic><topic>Glycerol - administration & dosage</topic><topic>Glycerol - isolation & purification</topic><topic>Humans</topic><topic>Immunology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Obesity - blood</topic><topic>Obesity - diagnosis</topic><topic>Obesity - diet therapy</topic><topic>Pharmacology/Toxicology</topic><topic>Pilot Projects</topic><topic>Rheumatology</topic><topic>Short Communication</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Vascular Endothelial Growth Factor A - blood</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parri, A.</creatorcontrib><creatorcontrib>Fitó, Montserrat</creatorcontrib><creatorcontrib>Torres, C. F.</creatorcontrib><creatorcontrib>Muñoz-Aguayo, D.</creatorcontrib><creatorcontrib>Schröder, H.</creatorcontrib><creatorcontrib>Cano, J. F.</creatorcontrib><creatorcontrib>Vázquez, L.</creatorcontrib><creatorcontrib>Reglero, G.</creatorcontrib><creatorcontrib>Covas, María-Isabel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Inflammopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parri, A.</au><au>Fitó, Montserrat</au><au>Torres, C. F.</au><au>Muñoz-Aguayo, D.</au><au>Schröder, H.</au><au>Cano, J. F.</au><au>Vázquez, L.</au><au>Reglero, G.</au><au>Covas, María-Isabel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alkylglycerols reduce serum complement and plasma vascular endothelial growth factor in obese individuals</atitle><jtitle>Inflammopharmacology</jtitle><stitle>Inflammopharmacol</stitle><addtitle>Inflammopharmacology</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>24</volume><issue>2-3</issue><spage>127</spage><epage>131</epage><pages>127-131</pages><issn>0925-4692</issn><eissn>1568-5608</eissn><abstract>Alkylglycerols (AKGs), isolated or present in shark liver oil have anti-inflammatory properties. Complement 3 (C3) and 4 (C4) participate in lipid metabolism and in obesity, contributing to the metabolic syndrome and to the low-grade inflammation associated with obesity. In a randomized, controlled, crossover study, 26 non-diabetes obese individuals were assigned two preparations with low (LAC, 10 mg AKGs) and high (HAC, 20 mg AKGs) AKG content. Intervention periods were of 3 weeks preceded by 2-week washout periods in which shark liver oil was avoided. Cholesterol, C3, C4, and vascular endothelial growth factor (VEGF) decreased in a linear trend (
P
< 0.01) from baseline (control) to LAC and HAC. Values after HAC were significantly lower (
P
< 0.05) versus both baseline and after LAC. No adverse effects were observed or reported. Data from this pilot study open a promising field for the study of the beneficial effects of AKGs on cardiovascular risk factors in obese individuals.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>27188987</pmid><doi>10.1007/s10787-016-0265-4</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-4692 |
| ispartof | Inflammopharmacology, 2016-06, Vol.24 (2-3), p.127-131 |
| issn | 0925-4692 1568-5608 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1888966739 |
| source | Springer Nature |
| subjects | Adult Allergology Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - isolation & purification Biomarkers - blood Biomedical and Life Sciences Biomedicine Cross-Over Studies Dermatology Double-Blind Method Female Fish Oils - administration & dosage Fish Oils - isolation & purification Gastroenterology Glycerol - administration & dosage Glycerol - isolation & purification Humans Immunology Male Middle Aged Obesity - blood Obesity - diagnosis Obesity - diet therapy Pharmacology/Toxicology Pilot Projects Rheumatology Short Communication Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - blood Young Adult |
| title | Alkylglycerols reduce serum complement and plasma vascular endothelial growth factor in obese individuals |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T19%3A47%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alkylglycerols%20reduce%20serum%20complement%20and%20plasma%20vascular%20endothelial%20growth%20factor%20in%20obese%20individuals&rft.jtitle=Inflammopharmacology&rft.au=Parri,%20A.&rft.date=2016-06-01&rft.volume=24&rft.issue=2-3&rft.spage=127&rft.epage=131&rft.pages=127-131&rft.issn=0925-4692&rft.eissn=1568-5608&rft_id=info:doi/10.1007/s10787-016-0265-4&rft_dat=%3Cproquest_pubme%3E1888966739%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p217t-1d2dc724670a9b2cbb87fb2bbcd3d22eb7d0de467cf3cb80e66a5652a42ad62e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1792373219&rft_id=info:pmid/27188987&rfr_iscdi=true |